220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer
Titel:
220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer
Auteur:
Lordick, F. Schuler, M. Al-Batran, S.-E. Zvirbule, Z. Manikhas, G. Rusyn, A. Vinnyk, Y. Vynnychenko, I. Fadeeva, N. Nechaeva, M. Dudov, A. Gotovkin, E. Pecheniy, A. Bazin, I. Bondarenko, I. Melichar, B. Huber, C. Sahin, U. Tu¨ reci, O.